Back Talk

Is the Trump Administration the Cure the FDA Needs?

Finally, a Congress and president who see pharma as a resource and not a villain, Flaum writes.

Harness the Power of Paranoia to Disrupt Your Business

In short, CEOs can't be afraid to walk away from their most profitable line if another approach may lead to improved long-term outcomes.

Paying Lip Service to STEM Isn't Enough

I'm not suggesting that colleges become vocational schools. But don't you think they should also help young people prepare for the life they're going to be living?

Will Investors Reward Drugmakers That Limit Price Increases?

Now here comes the big question. Will the shareholders and directors of KaloBios and Allergan reward or punish their CEOs for what some may see as revenue-capping concessions?

How About a Moon Shot for Orphan Diseases?

You can see it everywhere: on TV and in newspapers and ads. The decades of struggle against cancer are paying off.

Moving Forward — Without the Promotion

Until now, your superiors have promoted you. Now it's your responsibility to show why you belong.

Why are We Still Shortchanging Women in the Workplace?

Why would any CEO tolerate a corporate culture that holds people back?

Zika Crisis Stresses Need for Pharma Industry

When pharmaceutical companies are needed, we're Jonas Salks; when we ask to be paid, we're Martin Shkrelis.

Right-to-Try Laws Take Sensible Approach to Reforming FDA Rules

The regulator's reliance on double-blind, placebo-controlled trials with exhaustive inclusion and exclusion criteria is incompatible with today's precision medicine.

Your PharmaScope 2016

If we don't clean up our act and do something about predatory pricing scandals, we'll wind up with Washington bureaucrats telling us what we can charge for our products.

OPINION

Why President Trump Won't Overhaul the FDA

Newsletters